

INDOLE-3-ACETIC ACID SAFETY DATA SHEET

IDENTIFICATION Product Identifier Product Number Distributor Name Distributor Address

Phone Number Emergency Phone Number (US only) Emergency Phone Number (International) Safety Data Sheet Issued by CAS-Number EC/ REACH Number Recommended Use

Restrictions on Use

2. HAZARD(S) IDENTIFICATION

GHS Classification GHS Label Elements, Including Precautionary statements Hazard Statements Precautionary Statements Hazards not otherwise classified (HNOC) by GHS

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonym(s)

TOKU-E USA [87-51-4] [201-748-2] Endogenous heterocyclic auxin plant hormone derived from Indole Not for human or animal use

Not a hazardous substance or mixture None

Indole-3-acetic acid

TOKU-E Company

(360) 734-1789

1 (800) 535-5053

+1 (352) 323-3500

715 W Orchard Dr, Suite 3 Bellingham, WA 98225

1014

None
None
None

3-Indoleacetic acid; IAA; Heteroauxin; Indol-3-ylacetic acid; IAA; Beta-Indoleacetic acid; Omega-Skatole carboxylic acid C₁₀H₉NO₂ 175.18 g/mol [87-51-4] [201-748-2] Not available None

Formula Molecular Weight CAS-Number EC-Number Index-Number Hazardous components

EIDST AID MEASURES .

4.	FIRST-AID MEASURES	
	General Advice	Consult a physician. Show this Safety Data Sheet to the medical provider
	If Inhaled	If breathed in, move person to fresh air. If not breathing, give artificial respiration. Consult a doctor
	In Case of Eye Contact	Rinse thoroughly with plenty of water for at least 15 minutes, consult a doctor
	If Swallowed	Never give anything by mouth to an unconscious person. Consult a doctor. Rinse mouth with water.
	Most important symptoms and effects, both acute and delayed	Please see Section 2 and/or Section 11
	Indication of any immediate medical attention and special treatment needed	No data available
5.	FIRE-FIGHTING MEASURES	
	Suitable Extinguishing Media	Water spray, alcohol-resistant foam, dry chemical, carbon dioxide
	Special Protective Equipment for Firefighters	Wear self-contained breathing apparatus
	Hazardous Combustion Products	Formed under fire conditions: Carbon and Nitrogen oxides
6.	ACCIDENTAL RELEASE MEASURES	
	General	Evacuate personnel to safe location
	Personal Precautions	Wear respiratory protection. Avoid dust formation and breathing vapors/mist/dust/gas. Ensure adequate ventilation
	Environmental Precautions	Prevent spillage, do not let product enter drains
	Methods of Containment and Cleanup	Place in suitable, closed containers for licensed disposal. Avoid dust formation.
7.	HANDLING AND STORAGE	
	Precautions for Safe Handling	Avoid contact with skin and eyes. Provide exhaust ventilation in areas where dust if formed
	Precautions for Safe Storage	Keep container tightly closed and in a dry, well- ventilated place. Recommended storage temperature: -20°C
	Incompatibilities	None known

8. EXPOSURE CONTROLS/ PERSONAL PROTECTION

Contains no substances with occupational exposure limit values

	PPE: Respiratory protection	Where risk assessment shows air-purifying respirators are appropriate, use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU)
	PPE: Hand Protection	Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal techniques to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices, and wash and dry hands
	PPE: Eye Protection	Use a face shield and safety glasses. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166 (EU)
	PPE: Skin and Body Protection	Handle with gloves. Wear protective clothing. Choose body protection according to the amount and concentration of the dangerous substance at the work place. When deemed needed according to the concentration and amount of this product, use a complete body suit
9.	PHYSICAL/CHEMICAL PROPERTIES	
	Appearance	White-to-tan crystalline powder
	pH Molting Doint/Erooging Doint	No data available
	Rolling Point/Freezing Point	No data available
	Duning Pullic	NU Uala avaliable

- Flash Point
- Ignition Temperature
- Autoignition Temperature
- Lower Explosion Limit
- Upper Explosion Limit
- Vapor Pressure
- Density
- Water Solubility
- Solubility in Other Solvents
- Partition Coefficient: n-octanol/water Optical Rotation
- Absorbance (290nm, 5% in H₂O)
- Water content (Karl Fisher)
- 165-170°C No data available Not soluble Ethanol: soluble No data available No data available No data available No data available No data available

10. STABILITY AND REACTIVITY

Chemical Stability Possibility of Hazardous Reactions Conditions to Avoid Materials to Avoid Hazardous Decomposition Products

11. TOXICOLOGICAL INFORMATION

Oral LD₅₀ Inhalation LC₅₀ Dermal LD₅₀ Intraperitoneal LD₅₀ Intravenous LD₅₀ Skin Corrosion/Irritation Serious Eye Damage/ Eye Irritation Respiratory or Skin Sensitization Germ Cell Mutagenicity

Carcinogenicity

Reproductive Toxicity Teratogenicity Stable under recommended storage conditions No data available Moisture Strong oxidizing agents Carbon and Nitrogen oxides formed under fire conditions

Rat: >500 mg/kg No data available No data available Mouse: 150 mg/kg No data available No data available No data available No data available Gene conversion, mitotic recombination, sex chromosome loss, and nondisjunction observed in organism Aspergillus nidulans at dosage 1150 umol/L. DNA damage observed to salmon sperm at dosage 250 µmol/L. Subcutaneous injection into mice at dosage 2000 mg/kg/20W-I resulted in TD_{L0} with the following effects: Tumorigenic - equivocal tumorigenic agent by RTECS criteria and tumor types after systemic administration not seen spontaneously. IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible, or confirmed human carcinogen by IARC ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA No data available

Oral exposure to female rats 7-15 days after conception at dosage 4500 mg/kg resulted in TD_{Lo} with specific craniofacial (including nose

Specific Target Organ Toxicity: Single Exposure (Globally Harmonized System) Specific Target Organ Toxicity: Repeated Exposure (Globally Harmonized System) **Aspiration Hazard** Potential Health Effects Signs and Symptoms of Exposure

Synergistic Effects Additional Information

12. ECOLOGICAL INFORMATION

	Toxicity	No data available
	Persistence and Degradability	No data available
	Bioaccumulative Potential	No data available
	Mobility in Soil	No data available
	PBT and vPvB Assessment	No data available
Treat as if harmful if released into environment		

13. DISPOSAL CONSIDERATIONS Product Dispose of product through a licensed disposal company Dispose of as unused product **Contaminated Packaging 14. TRANSPORTATION INFORMATION** DOT (US) Not Dangerous Goods IMDG Not Dangerous Goods

15. REGULATORY INFORMATION

IATA

and tongue) developmental abnormalities to the offspring.

Oral exposure to female rats 7-15 days after conception at dosage 450 mg/kg resulted in TD_{Lo} with specific developmental abnormalities to the musculoskeletal system of the offspring. Oral exposure to female mice 7-15 days after conception at dosage 4500 mg/kg resulted in TD_{Lo} with effects on the embryo or fetus including fetotoxicity, fetal death, and specific developmental abnormalities to the central nervous system, eyes, ears, craniofacial region (including nose and tongue), and musculoskeletal system. No data available

No data available

No data available See Section 2, Hazard(s) Identification To the best of our knowledge, the chemical, physical, and toxicological properties of this material have not been thoroughly investigated No data available RTECS: NL3150000

ble

Not Dangerous Goods

SARA 302 Components	No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302
SARA 313 Components	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313
SARA 311/312 Hazards	No SARA 311/312 Hazards
Massachusetts Right to Know Components	No components are subject to the Massachusetts Right to Know Act
Pennsylvania Right to Know Components	Indol-3-ylacetic acid
	CAS-Number [87-51-4]
	Revision Date: Not available
New Jersey Right to Know Components	Indol-3-ylacetic acid
	CAS-Number [87-51-4]
	Revision Date: Not available
California Prop. 65 Components	This product does not contain any chemicals
	known to the State of California to cause, birth
	defects, cancer, or any other reproductive harm
EU Information	SDS in accordance with REACH 1907/2006
	EC Number [201-748-2]
	CAS-Number [87-51-4]
	Name: indol-3-ylacetic acid
	Envisaged Registration Deadline: 30/11/2010
	See GHS Information under Section 2, Hazard
	Identification

16. OTHER INFORMATION

Date of last revision: 2016-04-15

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. TOKU-E Company shall not be held liable for any damage resulting from handling or from contact with the above product. Please see reverse side of invoice or packing slip for additional terms and conditions of sale.